AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02581423
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m\^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
Trial: NCT00985439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules 2 Single-dose
Trial: NCT02784808
Drug: Non-Biologic DMARDs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
Trial: NCT02071121
Drug: BIIB061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB061 capsules for oral administration
Trial: NCT02071121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB061 matching placebo capsules
Trial: NCT01580618
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
Trial: NCT03919799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive substance
Trial: NCT00382577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01433614
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
Trial: NCT01031355
Drug: Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
Trial: NCT00088478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03951402
Drug: Placebo matching CG5503 PR tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet to CG5503 PR tablet.
Trial: NCT00465205
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral twice daily
Trial: NCT01482884
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sc injections of every 2 weeks for 12 weeks.
Trial: NCT01234298
Drug: SPD489 High-Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
Trial: NCT01234298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule taken once-daily for up to 26 weeks
Trial: NCT00539136
Drug: GSK561679 tablet or solution
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00439244
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
Trial: NCT00439244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
Trial: NCT00070174
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00070174
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02021240
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02888444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 0.5mg tablets taken twice daily
Trial: NCT00018200
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
Trial: NCT00018200
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
Trial: NCT00887978
Drug: UT-15C SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treprostinil diolamine sustained release tablets
Trial: NCT00887978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01188863
Drug: 300 mg LX4211 (150 mg tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of two 150 mg tablets LX4211
Trial: NCT01188863
Drug: 300 mg LX4211 (50 mg tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of six 50 mg tablets LX4211
Trial: NCT01188863
Drug: 300 mg LX4211 (liquid)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
Trial: NCT02305056
Drug: C13 N15 Valine
RxNorm normalized name: SOR-C13
DrugBank: SOR-C13 (DB15366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C13 N15 Valine administration
Trial: NCT03996252
Drug: Calcipotriene 0.005% Foam
RxNorm normalized name: CALCIPOTRIENE 0.005% FOAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
Trial: NCT03996252
Drug: Efudex 5% Topical Cream
RxNorm normalized name: Efudex 5% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
Trial: NCT01543698
Drug: LGX818
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01543698
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01543698
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02974166
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
Trial: NCT00566371
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03119077
Drug: BAY1161116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
Trial: NCT03119077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
Trial: NCT04374032
Drug: The standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina
Trial: NCT02264197
Drug: BIBX 245 CL - fed
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02824874
Drug: Duvie Tab. 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duvie Tab. 0.5mg\*1T/day for 5days, QD, PO
Trial: NCT02824874
Drug: Duvie Tab. 0.5mg + Januvia Tab. 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duvie Tab. 0.5mg + Januvia Tab.100mg\*1T/day for 5 dyas, QD, PO
Trial: NCT04090021
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use in a drug combination for H. pylori eradication
Trial: NCT00943059
Drug: Cellulosum Mycrocryst
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
Trial: NCT01575769
Drug: RoActemra/Actemra (tocilizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
Trial: NCT00006258
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006258
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03034356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01839851
Drug: Treatment with any inhaled corticosteroid
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of any inhaled corticosteroid (daily frequency and dose will be registered)
Trial: NCT01839851
Drug: Treatment with any intranasal glucocorticoid
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
Trial: NCT03879707
Drug: Melatonin 5 mg
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin is known to induce sleep
Trial: NCT03879707
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02557620
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin)once daily or once weekly.
Trial: NCT03675880
Drug: TAB014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)
Trial: NCT02499029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical looking placebo pills were administered each week.
Trial: NCT04635943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.
Trial: NCT00429416
Drug: L-leucyl-L-leucine Methyl Ester (LLME)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
Trial: NCT00823368
Drug: STX209
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00429416
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 1gm/m2 prior to HSCT infusion
Trial: NCT02259868
Drug: BILR 355 BS /1B, current low dose formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02259868
Drug: BILR 355 BS /1B, current high dose formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02259868
Drug: BILR 355 BS - Suspension high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00643227
Drug: azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
Trial: NCT00105469
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
Trial: NCT02720471
Drug: Locoregional anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh
Trial: NCT02720471
Drug: peroperative infiltration of local anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peroperative infiltration of local anesthetics
Trial: NCT00621985
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
Trial: NCT03229278
Drug: Enzyme Inhibitor Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given trigriluzole PO
Trial: NCT00630981
Drug: Pharmacological treatment (Quetiapine and/or Escitalopram)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
Trial: NCT00653744
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04467060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, fasting oral administration
Trial: NCT00574847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
Trial: NCT00691015
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02161367
Drug: Oral Suspending Vehicle
RxNorm normalized name: Base PCCA-PLUS Oral Suspending Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORA-Plus is an aqueous-based vehicle.~Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days
Trial: NCT03292588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study.
Trial: NCT01581814
Drug: Yasmin;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
Trial: NCT01468012
Drug: levodopa carbidopa and entacapone (LCE)
RxNorm normalized name: carbidopa / entacapone / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/100mg/200mg, twice daily
Trial: NCT01468012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo for LCE condition dosed twice daily
Trial: NCT01525537
Drug: administration of sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microgram sufentanil were given when SPI above 50 for more then 20 sec
Trial: NCT01525537
Drug: sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sufentanil was given at standard practise
Trial: NCT04506021
Drug: Bicarbonate Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution. no Intervention.
Trial: NCT00436683
Drug: Fermagate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablet 500mg
Trial: NCT00834561
Drug: Lamictal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Tablet
Trial: NCT02817191
Drug: Hylo-Comod eye drop
RxNorm normalized name: Hylocereus undatus fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
Trial: NCT02817191
Drug: Tears Naturale Forte eye drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
Trial: NCT01087398
Drug: Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2
Trial: NCT01087398
Drug: Cyclosporin, Methotrexate (GVHD prophylaxis)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)
Trial: NCT01167894
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
Trial: NCT02680379
Drug: Minocycline, then Minocycline/Lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
Trial: NCT02680379
Drug: Lovastatin, then Minocycline/Lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
Trial: NCT02568046
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard FOLFIRI regimen consists of Irinotecan (180 mg/m\^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m\^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m\^2 IV bolus, then 2400 mg/m\^2 infused over 46 hours).
Trial: NCT00471068
Drug: Placebo (Timolol Vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
Trial: NCT02998593
Drug: Bahman capsules
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Use of Bahman capsules for 3 months by patients.
Trial: NCT02998593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use of placebo capsules by patients for 3 months.
Trial: NCT01675960
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.
Trial: NCT03138876
Drug: Anti-seizure medication
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
Trial: NCT02599129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
Trial: NCT01698645
Drug: PecFent® (fentanyl) nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01501786
Drug: Ket10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
Trial: NCT01501786
Drug: Ket20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
Trial: NCT01228760
Drug: ASG-5ME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00070278
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00084721
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03769454
Drug: PP-001
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PP-001 eye drops
Trial: NCT02224040
Drug: ceftriaxone and azithromycin
RxNorm normalized name: cefixime and azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02224040
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02224040
Drug: azithromycin and cefixime
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01142726
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, oral, 2.5 mg, once weekly, 12 months